Literature DB >> 33638902

Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.

Elizabeth P Newberry1, Zoe Hall2,3, Yan Xie1, Elizabeth A Molitor1, Peter O Bayguinov4, Gregory W Strout4, James A J Fitzpatrick4,5,6, Elizabeth M Brunt7, Julian L Griffin2,3, Nicholas O Davidson1.   

Abstract

BACKGROUND AND AIMS: Human transmembrane 6 superfamily 2 (TM6SF2) variant rs58542926 is associated with NAFLD and HCC. However, conflicting reports in germline Tm6sf2 knockout mice suggest no change or decreased very low density lipoprotein (VLDL) secretion and either unchanged or increased hepatic steatosis, with no increased fibrosis. We generated liver-specific Tm6Sf2 knockout mice (Tm6 LKO) to study VLDL secretion and the impact on development and progression of NAFLD. APPROACH AND
RESULTS: Two independent lines of Tm6 LKO mice exhibited spontaneous hepatic steatosis. Targeted lipidomic analyses showed increased triglyceride species whose distribution and abundance phenocopied findings in mice with liver-specific deletion of microsomal triglyceride transfer protein. The VLDL triglyceride secretion was reduced with small, underlipidated particles and unchanged or increased apolipoprotein B. Liver-specific adeno-associated viral, serotype 8 (AAV8) rescue using either wild-type or mutant E167K-Tm6 reduced hepatic steatosis and improved VLDL secretion. The Tm6 LKO mice fed a high milk-fat diet for 3 weeks exhibited increased steatosis and fibrosis, and those phenotypes were further exacerbated when mice were fed fibrogenic, high fat/fructose diets for 20 weeks. In two models of HCC, either neonatal mice injected with streptozotocin (NASH/STAM) and high-fat fed or with diethylnitrosamine injection plus fibrogenic diet feeding, Tm6 LKO mice exhibited increased steatosis, greater tumor burden, and increased tumor area versus Tm6 flox controls. Additionally, diethylnitrosamine-injected and fibrogenic diet-fed Tm6 LKO mice administered wild-type Tm6 or E167K-mutant Tm6 AAV8 revealed significant tumor attenuation, with tumor burden inversely correlated with Tm6 protein levels.
CONCLUSIONS: Liver-specific Tm6sf2 deletion impairs VLDL secretion, promoting hepatic steatosis, fibrosis, and accelerated development of HCC, which was mitigated with AAV8- mediated rescue.
© 2021 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33638902      PMCID: PMC8390580          DOI: 10.1002/hep.31771

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.298


  43 in total

1.  Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.

Authors:  Paola Dongiovanni; Salvatore Petta; Cristina Maglio; Anna Ludovica Fracanzani; Rosaria Pipitone; Enrico Mozzi; Benedetta Maria Motta; Dorota Kaminska; Raffaela Rametta; Stefania Grimaudo; Serena Pelusi; Tiziana Montalcini; Anna Alisi; Marco Maggioni; Vesa Kärjä; Jan Borén; Pirjo Käkelä; Vito Di Marco; Chao Xing; Valerio Nobili; Bruno Dallapiccola; Antonio Craxi; Jussi Pihlajamäki; Silvia Fargion; Lars Sjöström; Lena M Carlsson; Stefano Romeo; Luca Valenti
Journal:  Hepatology       Date:  2015-02       Impact factor: 17.425

2.  Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia.

Authors:  Mathilde Di Filippo; Philippe Moulin; Pascal Roy; Marie Elisabeth Samson-Bouma; Sophie Collardeau-Frachon; Sabrina Chebel-Dumont; Noël Peretti; Jérôme Dumortier; Fabien Zoulim; Thierry Fontanges; Rossella Parini; Miriam Rigoldi; Francesca Furlan; Grazia Mancini; Dominique Bonnefont-Rousselot; Eric Bruckert; Jacques Schmitz; Jean Yves Scoazec; Sybil Charrière; Sylvie Villar-Fimbel; Frederic Gottrand; Béatrice Dubern; Diane Doummar; Francesca Joly; Marie Elisabeth Liard-Meillon; Alain Lachaux; Agnès Sassolas
Journal:  J Hepatol       Date:  2014-05-16       Impact factor: 25.083

3.  Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.

Authors:  Xiaobo Wang; Ze Zheng; Jorge Matias Caviglia; Kathleen E Corey; Tina M Herfel; Bishuang Cai; Ricard Masia; Raymond T Chung; Jay H Lefkowitch; Robert F Schwabe; Ira Tabas
Journal:  Cell Metab       Date:  2016-10-27       Impact factor: 27.287

4.  Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency.

Authors:  Yan Xie; Elizabeth P Newberry; Stephen G Young; Sylvie Robine; Robert L Hamilton; Jinny S Wong; Jianyang Luo; Susan Kennedy; Nicholas O Davidson
Journal:  J Biol Chem       Date:  2005-12-13       Impact factor: 5.157

5.  Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis.

Authors:  Luc Gailhouste; Yann Le Grand; Christophe Odin; Dominique Guyader; Bruno Turlin; Frédéric Ezan; Yoann Désille; Thomas Guilbert; Anne Bessard; Christophe Frémin; Nathalie Theret; Georges Baffet
Journal:  J Hepatol       Date:  2010-01-17       Impact factor: 25.083

6.  The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis.

Authors:  Carlos J Pirola; Silvia Sookoian
Journal:  Hepatology       Date:  2015-10-29       Impact factor: 17.425

Review 7.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

8.  Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk.

Authors:  Oddgeir L Holmen; He Zhang; Yanbo Fan; Daniel H Hovelson; Ellen M Schmidt; Wei Zhou; Yanhong Guo; Ji Zhang; Arnulf Langhammer; Maja-Lisa Løchen; Santhi K Ganesh; Lars Vatten; Frank Skorpen; Håvard Dalen; Jifeng Zhang; Subramaniam Pennathur; Jin Chen; Carl Platou; Ellisiv B Mathiesen; Tom Wilsgaard; Inger Njølstad; Michael Boehnke; Y Eugene Chen; Gonçalo R Abecasis; Kristian Hveem; Cristen J Willer
Journal:  Nat Genet       Date:  2014-03-16       Impact factor: 38.330

9.  The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation.

Authors:  Soumik BasuRay; Eriks Smagris; Jonathan C Cohen; Helen H Hobbs
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

10.  MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.

Authors:  Benedetta Donati; Paola Dongiovanni; Stefano Romeo; Marica Meroni; Misti McCain; Luca Miele; Salvatore Petta; Silvia Maier; Chiara Rosso; Laura De Luca; Ester Vanni; Stefania Grimaudo; Renato Romagnoli; Fabio Colli; Flaminia Ferri; Rosellina Margherita Mancina; Paula Iruzubieta; Antonio Craxi; Anna Ludovica Fracanzani; Antonio Grieco; Stefano Ginanni Corradini; Alessio Aghemo; Massimo Colombo; Giorgio Soardo; Elisabetta Bugianesi; Helen Reeves; Quentin M Anstee; Silvia Fargion; Luca Valenti
Journal:  Sci Rep       Date:  2017-07-03       Impact factor: 4.379

View more
  10 in total

Review 1.  NAFLD: Mechanisms, Treatments, and Biomarkers.

Authors:  Fatiha Nassir
Journal:  Biomolecules       Date:  2022-06-13

Review 2.  Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.

Authors:  Sílvia Vilarinho; Veeral Ajmera; Melanie Zheng; Rohit Loomba
Journal:  Hepatology       Date:  2021-10       Impact factor: 17.298

3.  Something to mTORC About in NASH.

Authors:  Brian N Finck
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-04-02

Review 4.  TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease.

Authors:  Fei Luo; Avash Das; Federico Oldoni
Journal:  Hepatol Commun       Date:  2021-09-16

Review 5.  Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).

Authors:  Jih-Kai Huang; Hsiang-Chun Lee
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

6.  Lack of VMP1 impairs hepatic lipoprotein secretion and promotes non-alcoholic steatohepatitis.

Authors:  Xiaoxiao Jiang; Sam Fulte; Fengyan Deng; Shiyuan Chen; Yan Xie; Xiaojuan Chao; Xi C He; Yuxia Zhang; Tiangang Li; Feng Li; Colin McCoin; E Matthew Morris; John Thyfault; Wanqing Liu; Linheng Li; Nicholas O Davidson; Wen-Xing Ding; Hong-Min Ni
Journal:  J Hepatol       Date:  2022-04-19       Impact factor: 30.083

7.  Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis.

Authors:  Wenzhen Zhu; Wenying Liang; Haocheng Lu; Lin Chang; Jifeng Zhang; Y Eugene Chen; Yanhong Guo
Journal:  Cells       Date:  2022-09-15       Impact factor: 7.666

8.  Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.

Authors:  Shenling Liao; Kang An; Zhi Liu; He He; Zhenmei An; Qiaoli Su; Shuangqing Li
Journal:  J Clin Lab Anal       Date:  2022-07-26       Impact factor: 3.124

Review 9.  Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies.

Authors:  Tingyu Fang; Hua Wang; Xiaoyue Pan; Peter J Little; Suowen Xu; Jianping Weng
Journal:  Int J Biol Sci       Date:  2022-09-06       Impact factor: 10.750

10.  Perturbation of TM6SF2 Expression Alters Lipid Metabolism in a Human Liver Cell Line.

Authors:  Asmita Pant; Yue Chen; Annapurna Kuppa; Xiaomeng Du; Brian D Halligan; Elizabeth K Speliotes
Journal:  Int J Mol Sci       Date:  2021-09-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.